These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38573063)

  • 1. Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis.
    Liu H; Chen J; Huang Y; Zhang Y; Ni Y; Xu N; Zhao F; Tang Y; Liu H; Sun G; Shen P; Liu Z; Huang J; Liao B; Zeng H
    Int J Surg; 2024 Jun; 110(6):3923-3936. PubMed ID: 38573063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
    Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
    JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis.
    Fujiwara Y; Karol AB; Joshi H; Reford E; Izadmehr S; Doroshow DB; Galsky MD
    Crit Rev Oncol Hematol; 2024 May; 197():104352. PubMed ID: 38614269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
    Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H
    J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.
    Shohdy KS; Villamar DM; Cao Y; Trieu J; Price KS; Nagy R; Tagawa ST; Molina AM; Sternberg CN; Nanus DM; Mosquera JM; Elemento O; Sonpavde GP; Grivas P; Vogelzang NJ; Faltas BM
    Br J Cancer; 2022 Feb; 126(3):430-439. PubMed ID: 35046520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma.
    Laukhtina E; Hassler MR; Pradere B; Yanagisawa T; Quhal F; Rajwa P; Sari Motlagh R; König F; Pallauf M; Kawada T; Mostafaei H; D'Andrea D; Enikeev D; Shariat SF
    Eur Urol Focus; 2022 Nov; 8(6):1683-1686. PubMed ID: 35562252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review.
    Crupi E; de Padua TC; Marandino L; Raggi D; Dyrskjøt L; Spiess PE; Sonpavde GP; Kamat AM; Necchi A
    Eur Urol Oncol; 2024 Feb; 7(1):44-52. PubMed ID: 37330413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
    Powles T; Assaf ZJ; Degaonkar V; Grivas P; Hussain M; Oudard S; Gschwend JE; Albers P; Castellano D; Nishiyama H; Daneshmand S; Sharma S; Sethi H; Aleshin A; Shi Y; Davarpanah N; Carter C; Bellmunt J; Mariathasan S
    Eur Urol; 2024 Feb; 85(2):114-122. PubMed ID: 37500339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis.
    Nader-Marta G; Monteforte M; Agostinetto E; Cinquini M; Martins-Branco D; Langouo M; Llombart-Cusac A; Cortés J; Ignatiadis M; Torri V; Apolone G; Cappelletti V; Pruneri G; de Azambuja E; Di Cosimo S
    ESMO Open; 2024 Mar; 9(3):102390. PubMed ID: 38460249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.
    Rose KM; Huelster HL; Meeks JJ; Faltas BM; Sonpavde GP; Lerner SP; Ross JS; Spiess PE; Grass GD; Jain RK; Kamat AM; Vosoughi A; Wang L; Wang X; Li R
    Nat Rev Urol; 2023 Jul; 20(7):406-419. PubMed ID: 36977797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic profiling of Chinese patients with urothelial carcinoma.
    Yang B; Zhao X; Wan C; Ma X; Niu S; Guo A; Wang J; Wang J; Sun D; Jiao S
    BMC Cancer; 2021 Feb; 21(1):162. PubMed ID: 33588785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis.
    Fang Z; Meng Q; Zhang B; Shi S; Liu J; Liang C; Hua J; Yu X; Xu J; Wang W
    Aging (Albany NY); 2020 Dec; 13(2):2031-2048. PubMed ID: 33318293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
    Alqahtani A; Alloghbi A; Coffin P; Yin C; Mukherji R; Weinberg BA
    Surg Oncol; 2023 Dec; 51():102007. PubMed ID: 37852124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of circulating tumor DNA in operable non-small cell lung cancer: a systematic review and reconstructed individual patient-data based meta-analysis.
    Chen D; Guo J; Huang H; Tian L; Xie Y; Wu Q
    BMC Med; 2023 Nov; 21(1):467. PubMed ID: 38012727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Serum Magnesium Levels and Outcomes of Atezolizumab in Patients With Metastatic Urothelial Carcinoma.
    Fukuokaya W; Akazawa K; Kimura T
    Anticancer Res; 2024 May; 44(5):2117-2123. PubMed ID: 38677745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
    Powles T; Assaf ZJ; Davarpanah N; Banchereau R; Szabados BE; Yuen KC; Grivas P; Hussain M; Oudard S; Gschwend JE; Albers P; Castellano D; Nishiyama H; Daneshmand S; Sharma S; Zimmermann BG; Sethi H; Aleshin A; Perdicchio M; Zhang J; Shames DS; Degaonkar V; Shen X; Carter C; Bais C; Bellmunt J; Mariathasan S
    Nature; 2021 Jul; 595(7867):432-437. PubMed ID: 34135506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
    Agarwal N; Pal SK; Hahn AW; Nussenzveig RH; Pond GR; Gupta SV; Wang J; Bilen MA; Naik G; Ghatalia P; Hoimes CJ; Gopalakrishnan D; Barata PC; Drakaki A; Faltas BM; Kiedrowski LA; Lanman RB; Nagy RJ; Vogelzang NJ; Boucher KM; Vaishampayan UN; Sonpavde G; Grivas P
    Cancer; 2018 May; 124(10):2115-2124. PubMed ID: 29517810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
    Jones RP; Pugh SA; Graham J; Primrose JN; Barriuso J
    Eur J Cancer; 2021 Feb; 144():368-381. PubMed ID: 33422803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma.
    Nakano K; Koh Y; Yamamichi G; Yumiba S; Tomiyama E; Matsushita M; Hayashi Y; Wang C; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Kiyotani K; Katayama K; Yamaguchi R; Imoto S; Imamura R; Nonomura N; Uemura M
    Cancer Sci; 2022 May; 113(5):1830-1842. PubMed ID: 35293110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.
    Vandekerkhove G; Lavoie JM; Annala M; Murtha AJ; Sundahl N; Walz S; Sano T; Taavitsainen S; Ritch E; Fazli L; Hurtado-Coll A; Wang G; Nykter M; Black PC; Todenhöfer T; Ost P; Gibb EA; Chi KN; Eigl BJ; Wyatt AW
    Nat Commun; 2021 Jan; 12(1):184. PubMed ID: 33420073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.